Report finds nirsevimab 80% effective at preventing RSV-associated ICU admissions
Nirsevimab was found to be 80% effective at preventing respiratory syncytial virus-associated intensive care unit admissions during the 2024-2025 RSV season, according to a Centers for Disease Control and Prevention report released Nov. 20. It also found the treatment to be 83% effective at preventing acute respiratory failure among infants admitted to an ICU with symptoms during their first RSV season. “These estimates support the recommendation for use of nirsevimab as a prevention strategy to protect infants against severe outcomes from RSV infection,” the CDC said.
Related News Articles
Perspective
May is Mental Health Awareness Month, a time to elevate a conversation that hospitals and health systems live every day. Behavioral health is inseparable from…
Headline
The Agency for Healthcare Research and Quality has issued a request for nominations for candidates to serve on the U.S. Preventive Services Task Force. While…
Headline
Obesity rates for U.S. children and teenagers have reached record highs, while rates for adults had a slight decline, according to reports by the Centers for…
Blog
The holiday season is often depicted as a time of joy and celebration, but for health care professionals it can also be a busy and emotionally demanding time…
Headline
The Advisory Committee on Immunization Practices Dec. 5 recommended individual-based decision-making for parents deciding whether to give the hepatitis B…
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult for…